mouse anti bdnf Search Results


90
Promega polyclonal chicken igy anti-mouse bdnf
Animal treatment protocol. Mice were sensitised to OVA adsorbed to Al(OH)3 or vehicle alone by intraperitoneal injections on days 1, 14 and 21. Prior to analysis, animals received two consecutive local aerosol challenges of 1% OVA (w v−1) diluted in PBS or PBS alone and delivered by 20-min aerosolisation on days 26 and 27. Intranasal application of <t>polyclonal</t> chicken IgY (isotype antibody) or anti-mouse <t>BDNF</t> was performed 3 h before each airway allergen challenge. In addition, animals received the antibodies i.p. on day 25. The response to acute allergen exposure was measured on day 35 in the body plethysmograph. All animals were analysed 24 h after the last challenge. Abbreviations: intraperitoneally (i.p.), intranasally (i.n.), aerosol challenge (aerosol).
Polyclonal Chicken Igy Anti Mouse Bdnf, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/polyclonal+chicken+igy+anti+mouse+bdnf/pmc01574219-88-0-25
Average 90 stars, based on 1 article reviews
polyclonal chicken igy anti-mouse bdnf - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Promega mouse bdnf elisa kit
Animal treatment protocol. Mice were sensitised to OVA adsorbed to Al(OH)3 or vehicle alone by intraperitoneal injections on days 1, 14 and 21. Prior to analysis, animals received two consecutive local aerosol challenges of 1% OVA (w v−1) diluted in PBS or PBS alone and delivered by 20-min aerosolisation on days 26 and 27. Intranasal application of <t>polyclonal</t> chicken IgY (isotype antibody) or anti-mouse <t>BDNF</t> was performed 3 h before each airway allergen challenge. In addition, animals received the antibodies i.p. on day 25. The response to acute allergen exposure was measured on day 35 in the body plethysmograph. All animals were analysed 24 h after the last challenge. Abbreviations: intraperitoneally (i.p.), intranasally (i.n.), aerosol challenge (aerosol).
Mouse Bdnf Elisa Kit, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/mouse+anti+bdnf+elisa+kit/pm19571795-70-25-32
Average 90 stars, based on 1 article reviews
mouse bdnf elisa kit - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Merck KGaA anti-bdnf mouse monoclonal antibody
NLC secrete <t>BDNF,</t> thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .
Anti Bdnf Mouse Monoclonal Antibody, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/anti+bdnf+mouse+monoclonal+antibody/pmc07387561-128-5-12
Average 90 stars, based on 1 article reviews
anti-bdnf mouse monoclonal antibody - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Merck KGaA anti-bdnf mouse antibody clone #35928.11
NLC secrete <t>BDNF,</t> thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .
Anti Bdnf Mouse Antibody Clone #35928.11, supplied by Merck KGaA, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/anti+bdnf+mouse+antibody+clone++35928+11/pm24815386-44-8-14
Average 90 stars, based on 1 article reviews
anti-bdnf mouse antibody clone #35928.11 - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Promega mouse cross-reactive chicken anti-human brain-derived neurotrophic factor (bdnf)
NLC secrete <t>BDNF,</t> thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .
Mouse Cross Reactive Chicken Anti Human Brain Derived Neurotrophic Factor (Bdnf), supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/mouse+cross+reactive+chicken+anti+human+brain+derived+neurotrophic+factor++bdnf+/us09782464-1530-22-34
Average 90 stars, based on 1 article reviews
mouse cross-reactive chicken anti-human brain-derived neurotrophic factor (bdnf) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Chemicom Inc mouse anti-brain-derived neutrophic factor (bdnf)
NLC secrete <t>BDNF,</t> thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .
Mouse Anti Brain Derived Neutrophic Factor (Bdnf), supplied by Chemicom Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/mouse+anti+brain+derived+neutrophic+factor++bdnf+/pm20830611-61-39-45
Average 90 stars, based on 1 article reviews
mouse anti-brain-derived neutrophic factor (bdnf) - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier

90
Promega anti-bdnf mouse monoclonal igg
NLC secrete <t>BDNF,</t> thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .
Anti Bdnf Mouse Monoclonal Igg, supplied by Promega, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+anti+bdnf/anti+bdnf+mouse+monoclonal+igg/pm18692128-64-17-21
Average 90 stars, based on 1 article reviews
anti-bdnf mouse monoclonal igg - by Bioz Stars, 2026-09
90/100 stars
  Buy from Supplier



N/A
Mouse Anti-Human Brain-Derived Neurotrophic Factor / BDNF (500 µg)
  Buy from Supplier

Image Search Results


Animal treatment protocol. Mice were sensitised to OVA adsorbed to Al(OH)3 or vehicle alone by intraperitoneal injections on days 1, 14 and 21. Prior to analysis, animals received two consecutive local aerosol challenges of 1% OVA (w v−1) diluted in PBS or PBS alone and delivered by 20-min aerosolisation on days 26 and 27. Intranasal application of polyclonal chicken IgY (isotype antibody) or anti-mouse BDNF was performed 3 h before each airway allergen challenge. In addition, animals received the antibodies i.p. on day 25. The response to acute allergen exposure was measured on day 35 in the body plethysmograph. All animals were analysed 24 h after the last challenge. Abbreviations: intraperitoneally (i.p.), intranasally (i.n.), aerosol challenge (aerosol).

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Animal treatment protocol. Mice were sensitised to OVA adsorbed to Al(OH)3 or vehicle alone by intraperitoneal injections on days 1, 14 and 21. Prior to analysis, animals received two consecutive local aerosol challenges of 1% OVA (w v−1) diluted in PBS or PBS alone and delivered by 20-min aerosolisation on days 26 and 27. Intranasal application of polyclonal chicken IgY (isotype antibody) or anti-mouse BDNF was performed 3 h before each airway allergen challenge. In addition, animals received the antibodies i.p. on day 25. The response to acute allergen exposure was measured on day 35 in the body plethysmograph. All animals were analysed 24 h after the last challenge. Abbreviations: intraperitoneally (i.p.), intranasally (i.n.), aerosol challenge (aerosol).

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques: Aerosol

Overview of experiments and animal numbers

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Overview of experiments and animal numbers

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques: Aerosol

Effect of anti-BDNF treatment on allergen-induced airway obstruction by HBP. Measurement of expiratory flow in response to OVA (intranasal application during continuous measurement of airflow in the HBP). (a) Integration of EF50 values between 15 and 25 min after OVA application. (b) Time course of n=11 animals in each group. Data from three separate experiments are shown. Grey bar: possible artefacts from OVA application. The error bars represent standard error of the mean (s.e.m.). Student́s t-test: ***P<0.001.

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Effect of anti-BDNF treatment on allergen-induced airway obstruction by HBP. Measurement of expiratory flow in response to OVA (intranasal application during continuous measurement of airflow in the HBP). (a) Integration of EF50 values between 15 and 25 min after OVA application. (b) Time course of n=11 animals in each group. Data from three separate experiments are shown. Grey bar: possible artefacts from OVA application. The error bars represent standard error of the mean (s.e.m.). Student́s t-test: ***P<0.001.

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques:

Effect of BDNF and anti-BDNF treatment on inflammation. (a, b) Cytokine levels in BALF. IL-4, IL-5 and IFN-γ were measured in BALF from nonsensitised or OVA-sensitised mice 24 h after aerosol challenge by ELISA. The BAL recovery was 1.4±0.2 ml in all groups. (c, d) Cell differentiation in BALF after OVA aerosol challenge on day 28. Lymphocytes, macrophages, eosinophils and neutrophils were differentiated according to morphological criteria in BALF from nonsensitised or OVA-sensitised mice 24 h after the last aerosol challenge. (e) Cell differentiation in BALF 24 h after nasal OVA challenge on day 36. Student's t-test did not reveal any statistically significant difference (P<0.05) between groups. In all, 12 mice were analysed in each group, in two separate experiments. The error bars represent standard deviation (s.d.).

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Effect of BDNF and anti-BDNF treatment on inflammation. (a, b) Cytokine levels in BALF. IL-4, IL-5 and IFN-γ were measured in BALF from nonsensitised or OVA-sensitised mice 24 h after aerosol challenge by ELISA. The BAL recovery was 1.4±0.2 ml in all groups. (c, d) Cell differentiation in BALF after OVA aerosol challenge on day 28. Lymphocytes, macrophages, eosinophils and neutrophils were differentiated according to morphological criteria in BALF from nonsensitised or OVA-sensitised mice 24 h after the last aerosol challenge. (e) Cell differentiation in BALF 24 h after nasal OVA challenge on day 36. Student's t-test did not reveal any statistically significant difference (P<0.05) between groups. In all, 12 mice were analysed in each group, in two separate experiments. The error bars represent standard deviation (s.d.).

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques: Aerosol, Enzyme-linked Immunosorbent Assay, Cell Differentiation, Standard Deviation

Effect of BDNF on airway hyper-responsiveness in response to EFS. Airway hyper-responsiveness was measured in response to EFS. The frequency that caused 50% of maximal airway smooth muscle constriction was defined as ES50. Airway contractility was expressed as mean±s.d. Statistics were performed using t-test with Welch's correction. P<0.05 was regarded as a statistically significant difference. (a) Nonsensitised BALB/c mice were treated intranasally either with recombinant human BDNF (5 μg ml−1, 50 μl) or BSA (0.1%, 50 μl) as a control on two consecutive days. AHR was measured 24 h after the last treatment. In all, 12 animals were examined in each group in two separate experiments. (a) OVA-sensitised Balb/c mice were treated intranasally either with anti-BDNF (500 μg ml−1, 50 μl) or istotype IgY (500 μg ml−1, 50 μl) as a control on two consecutive days, 3 h before OVA aerosol challenge. In addition, the animals received 100 μl of the antibody solution i.p. 24 h before the first OVA challenge (day 25). AHR was measured 24 h after the last treatment. A total of 12 animals were examined in each group in two separate experiments.

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Effect of BDNF on airway hyper-responsiveness in response to EFS. Airway hyper-responsiveness was measured in response to EFS. The frequency that caused 50% of maximal airway smooth muscle constriction was defined as ES50. Airway contractility was expressed as mean±s.d. Statistics were performed using t-test with Welch's correction. P<0.05 was regarded as a statistically significant difference. (a) Nonsensitised BALB/c mice were treated intranasally either with recombinant human BDNF (5 μg ml−1, 50 μl) or BSA (0.1%, 50 μl) as a control on two consecutive days. AHR was measured 24 h after the last treatment. In all, 12 animals were examined in each group in two separate experiments. (a) OVA-sensitised Balb/c mice were treated intranasally either with anti-BDNF (500 μg ml−1, 50 μl) or istotype IgY (500 μg ml−1, 50 μl) as a control on two consecutive days, 3 h before OVA aerosol challenge. In addition, the animals received 100 μl of the antibody solution i.p. 24 h before the first OVA challenge (day 25). AHR was measured 24 h after the last treatment. A total of 12 animals were examined in each group in two separate experiments.

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques: Recombinant, Control, Aerosol

Effect of anti-BDNF treatment on airway hyper-responsiveness in response to methacholine and capsaicin by HBP. (a) Dose–response curve of expiratory flow (EF50) in response to inhaled methacholine. (b) Dose–response curve of expiratory flow (EF50) in response to inhaled capsaicin. (c) Dose–response curve of sensory irritation (TB) in response to inhaled methacholine. (d) Dose–response curve of sensory irritation (TB) in response to inhaled capsaicin. The error bars represent standard error of the mean (s.e.m.), n=8–10 animals in each group in three separate experiments. Student's t-test: *P<0.05. (a) Nonsensitised against OVA-sensitised+isotype, (d) OVA-sensitised+isotype against OVA-sensitised+anti-BDNF.

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Effect of anti-BDNF treatment on airway hyper-responsiveness in response to methacholine and capsaicin by HBP. (a) Dose–response curve of expiratory flow (EF50) in response to inhaled methacholine. (b) Dose–response curve of expiratory flow (EF50) in response to inhaled capsaicin. (c) Dose–response curve of sensory irritation (TB) in response to inhaled methacholine. (d) Dose–response curve of sensory irritation (TB) in response to inhaled capsaicin. The error bars represent standard error of the mean (s.e.m.), n=8–10 animals in each group in three separate experiments. Student's t-test: *P<0.05. (a) Nonsensitised against OVA-sensitised+isotype, (d) OVA-sensitised+isotype against OVA-sensitised+anti-BDNF.

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques:

Tachykinin containing sensory neurons from ovalbumin-sensitised mice

Journal:

Article Title: Brain-derived neurotrophic factor (BDNF) contributes to neuronal dysfunction in a model of allergic airway inflammation

doi: 10.1038/sj.bjp.0705638

Figure Lengend Snippet: Tachykinin containing sensory neurons from ovalbumin-sensitised mice

Article Snippet: Polyclonal chicken IgY anti-mouse BDNF (2 × 25 μ l) (500 μ g ml −1 ) or isotype antibody (500 μ g ml −1 ) (Promega, Madison, U.S.A.) solved in sterile PBS was instilled intranasally 3 h before each airway allergen challenge.

Techniques:

NLC secrete BDNF, thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .

Journal: Scientific Reports

Article Title: BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells

doi: 10.1038/s41598-020-69307-1

Figure Lengend Snippet: NLC secrete BDNF, thereby protecting B-CLL cells from apoptosis. ( a ) Representative western blots showing expression of BDNF in lysates of NLC from two independent patient samples (n = 5). ( b ) Immunofluorescence analysis of BDNF (red) expression in NLC by confocal microscopy. ( c ) Relative expression of BDNF mRNA by normal healthy monocytes (n = 6) and NLC isolated from B-CLL patients (n = 6), as determined by RT-qPCR. ( d ) Representative western blots showing BDNF expression in supernatants of two independent NLC culture (n = 6). ( e ) Representative western blots showing BDNF expression by B-CLL cells cultured alone, with autologous NLC, or with autologous NLC plus an anti-BDNF blocking antibody (anti-hBDNF; 200 ng/mL) for 48 h. The three conditions for each patient assessed on the same western blot, which has been cropped to present only relevant data. The uncropped western blot membranes are shown in Supplementary Fig. ( f ) Quantification of BDNF protein from independent patient samples (n = 5). ( g ) Relative expression of BDNF mRNA by B-CLL cells cultured alone or with autologous NLC for 48 h, as determined by RT-qPCR (n = 7). ( h ) Flow cytometry analysis of cell death, as assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured for 72 h either alone, with autologous NLC, or with autologous NLC plus an anti-BDNF antibody (200 ng/mL). Cell death was assessed by excluding annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. Blots are cropped for clarity; full-length blots are shown in the Supplementary Fig. .

Article Snippet: BDNF was neutralized using an anti-BDNF mouse monoclonal antibody (200 ng/mL; #GF35L, Merck Millipore).

Techniques: Western Blot, Expressing, Immunofluorescence, Confocal Microscopy, Isolation, Quantitative RT-PCR, Cell Culture, Blocking Assay, Flow Cytometry, Staining

The effects of BDNF on B-CLL pro-survival signaling are similar to those of BAFF, APRIL, and CXCL12 combined. ( a ) Representative western blot showing expression of NTSR2, p-Src, Src, and Bcl-2 by B-CLL cells isolated from patients. Cells were either co-cultured for 48 h with autologous NLC or cultured alone in complete medium supplemented (as indicated) with exogenous human (h) CXCL12 (100 ng/mL), BAFF (2 ng/mL), APRIL (25 ng/mL), or BDNF (100 ng/mL). (b,c,d), full-length blots are shown in the Supplementary Fig. . Quantification of NTSR2 ( b ), p-Src ( c ), and Bcl-2 ( d ) expression in four different patient samples. Data are presented as the mean ± SEM from at least three independent experiments, (* p < 0.05, ** p < 0.01). Blots are cropped for clarity; full blots are shown in the Supplementary Fig. .

Journal: Scientific Reports

Article Title: BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells

doi: 10.1038/s41598-020-69307-1

Figure Lengend Snippet: The effects of BDNF on B-CLL pro-survival signaling are similar to those of BAFF, APRIL, and CXCL12 combined. ( a ) Representative western blot showing expression of NTSR2, p-Src, Src, and Bcl-2 by B-CLL cells isolated from patients. Cells were either co-cultured for 48 h with autologous NLC or cultured alone in complete medium supplemented (as indicated) with exogenous human (h) CXCL12 (100 ng/mL), BAFF (2 ng/mL), APRIL (25 ng/mL), or BDNF (100 ng/mL). (b,c,d), full-length blots are shown in the Supplementary Fig. . Quantification of NTSR2 ( b ), p-Src ( c ), and Bcl-2 ( d ) expression in four different patient samples. Data are presented as the mean ± SEM from at least three independent experiments, (* p < 0.05, ** p < 0.01). Blots are cropped for clarity; full blots are shown in the Supplementary Fig. .

Article Snippet: BDNF was neutralized using an anti-BDNF mouse monoclonal antibody (200 ng/mL; #GF35L, Merck Millipore).

Techniques: Western Blot, Expressing, Isolation, Cell Culture

Inhibiting BDNF in addition to BAFF, APRIL, and CXCR4 reverses NLC-mediated protection of B-CLL cells from apoptosis. ( a ) Representative western blot showing expression of p-Src and Bcl-2 by B-CLL cells isolated from patients. Cells were cultured (for 72 h) alone, with autologous NLC, or with autologous NLC plus single or combined inhibition of BAFF (anti-hBAFF, 100 ng/mL), APRIL (anti-hAPRIL, 500 ng/mL), CXCL12 receptor CXCR4 (AMD3100, 0.5 µg/mL), and BDNF (anti-hBDNF, 200 ng/mL). ( b – d ), full-length blots are shown in the Supplementary Fig. .Quantification of NTSR2 ( b ), p-Src ( c ) and Bcl-2 ( d ) expression in six independent experiments using six different patient samples. ( e ) Flow cytometry analysis of cell death, assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured (for 72 h) either alone, with autologous NLC, or with autologous NLC and single or combined inhibition of BAFF (anti-hBAFF, 100 ng/mL), APRIL (anti-hAPRIL, 500 ng/mL), CXCL12 receptor CXCR4 inhibition (AMD3100, 0.5 µg/mL), and BDNF (anti-hBDNF, 200 ng/mL). Cell death was assessed by exclusion of annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 different patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. ( f ) Schematic representation of the obtained results. NLC produce and secrete BDNF, which promotes survival of B-CLL cells by activating the Src signaling pathway and upregulating expression of Bcl-2. This newly described member of the NLC secretome appears to exert both complementary (alongside BAFF, APRIL and CXCL12) and independent effects. Here, we propose a model in which BDNF or pro-survival cytokines secreted by NLC within survival centers balance each other out to facilitate survival of B-CLL cells, and argue that simultaneous inhibition of BDNF signaling through the NTSR2-TrkB conditional oncogenic platform, along with inhibition of BAFF, APRIL and CXCR4/CXCL12, could cancel out NLC-mediated protection of B-CLL cells from apoptosis and restore normal cell death.

Journal: Scientific Reports

Article Title: BDNF belongs to the nurse-like cell secretome and supports survival of B chronic lymphocytic leukemia cells

doi: 10.1038/s41598-020-69307-1

Figure Lengend Snippet: Inhibiting BDNF in addition to BAFF, APRIL, and CXCR4 reverses NLC-mediated protection of B-CLL cells from apoptosis. ( a ) Representative western blot showing expression of p-Src and Bcl-2 by B-CLL cells isolated from patients. Cells were cultured (for 72 h) alone, with autologous NLC, or with autologous NLC plus single or combined inhibition of BAFF (anti-hBAFF, 100 ng/mL), APRIL (anti-hAPRIL, 500 ng/mL), CXCL12 receptor CXCR4 (AMD3100, 0.5 µg/mL), and BDNF (anti-hBDNF, 200 ng/mL). ( b – d ), full-length blots are shown in the Supplementary Fig. .Quantification of NTSR2 ( b ), p-Src ( c ) and Bcl-2 ( d ) expression in six independent experiments using six different patient samples. ( e ) Flow cytometry analysis of cell death, assessed by annexin V-fluorescein isothiocyanate/propidium iodide dual staining of B-CLL cells cultured (for 72 h) either alone, with autologous NLC, or with autologous NLC and single or combined inhibition of BAFF (anti-hBAFF, 100 ng/mL), APRIL (anti-hAPRIL, 500 ng/mL), CXCL12 receptor CXCR4 inhibition (AMD3100, 0.5 µg/mL), and BDNF (anti-hBDNF, 200 ng/mL). Cell death was assessed by exclusion of annexin V/propidium iodide-negative cells. Experiments were performed using n = 9 different patient samples. Data are presented as the mean ± SEM from at least three independent experiments (* p < 0.05, ** p < 0.01, *** p < 0.001). ns not significant. ( f ) Schematic representation of the obtained results. NLC produce and secrete BDNF, which promotes survival of B-CLL cells by activating the Src signaling pathway and upregulating expression of Bcl-2. This newly described member of the NLC secretome appears to exert both complementary (alongside BAFF, APRIL and CXCL12) and independent effects. Here, we propose a model in which BDNF or pro-survival cytokines secreted by NLC within survival centers balance each other out to facilitate survival of B-CLL cells, and argue that simultaneous inhibition of BDNF signaling through the NTSR2-TrkB conditional oncogenic platform, along with inhibition of BAFF, APRIL and CXCR4/CXCL12, could cancel out NLC-mediated protection of B-CLL cells from apoptosis and restore normal cell death.

Article Snippet: BDNF was neutralized using an anti-BDNF mouse monoclonal antibody (200 ng/mL; #GF35L, Merck Millipore).

Techniques: Western Blot, Expressing, Isolation, Cell Culture, Inhibition, Flow Cytometry, Staining